Viatris R&D decreased by 9.5% to $248.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.0%, from $222.00M to $248.60M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 6.5% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $147.70M | $152.10M | $267.20M | $142.30M | $162.60M | $174.90M | $182.40M | $182.90M | $208.30M | $211.20M | $202.80M | $199.70M | $204.10M | $198.40M | $206.50M | $222.00M | $218.80M | $250.40M | $274.70M | $248.60M |
| QoQ Change | — | +3.0% | +75.7% | -46.7% | +14.3% | +7.6% | +4.3% | +0.3% | +13.9% | +1.4% | -4.0% | -1.5% | +2.2% | -2.8% | +4.1% | +7.5% | -1.4% | +14.4% | +9.7% | -9.5% |
| YoY Change | — | — | — | — | +10.1% | +15.0% | -31.7% | +28.5% | +28.1% | +20.8% | +11.2% | +9.2% | -2.0% | -6.1% | +1.8% | +11.2% | +7.2% | +26.2% | +33.0% | +12.0% |
Range$142.30M – $274.70M
CAGR+11.6%
Avg YoY Growth+10.9%
Median YoY Growth+11.2%
R&D at Other Companies
Frequently Asked Questions
- What is Viatris's r&d?
- Viatris (VTRS) reported r&d of $248.60M in Q1 2026.
- How has Viatris's r&d changed year-over-year?
- Viatris's r&d increased by 12.0% year-over-year, from $222.00M to $248.60M.
- What is the long-term trend for Viatris's r&d?
- Over 4 years (2021 to 2025), Viatris's r&d has grown at a 6.5% compound annual growth rate (CAGR), from $751.10M to $965.90M.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.